Neuren Pharmaceuticals Limited (OTCMKTS:NURPF – Get Free Report) shares traded down 5.4% on Wednesday . The company traded as low as C$6.86 and last traded at C$6.86. 1,750 shares traded hands during mid-day trading, an increase of 141% from the average session volume of 725 shares. The stock had previously closed at C$7.25.
Neuren Pharmaceuticals Stock Performance
The company has a 50-day simple moving average of C$8.11 and a 200-day simple moving average of C$8.40.
Neuren Pharmaceuticals Company Profile
Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. It develops and commercializes DAYBUE (trofinetide), which has been registered to treat Rett syndrome in adults and pediatric patients 2 years of age and older, as well as in Phase 2 clinical trial to treat Fragile X syndrome.
See Also
- Five stocks we like better than Neuren Pharmaceuticals
- Election Stocks: How Elections Affect the Stock Market
- FedEx Delivers Another Crushing Blow to Its Stock Price
- How Investors Can Find the Best Cheap Dividend Stocks
- Analysts Stay Bullish on Rocket Lab as Signs of a Bottom Emerge
- What is the Nikkei 225 index?
- Micron Stock Will Retest All-Time Highs This Year
Receive News & Ratings for Neuren Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neuren Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
